Arazlo - (0.045% Lotion, Topical)

Generic Name	Tazarotene	Innovator	Bausch health
Dosage	0.045% Lotion, Topical	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	ARAZLO is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*******	*** / *********	*** **, ****	*******	****	******* *** **** *** *** ****

Chronology Of Events